Central serous chorioretinopathy (CSC), sometimes called central serous retinopathy, happens when fluid leaks from the choroid and collects under the central retina (macula). This creates a small ‘blister’ that blurs central vision, warps straight lines and can dull colours. It often affects one eye, may settle in weeks to months, but can recur or persist.
Here we explain treatment for central serous chorioretinopathy: when observation is appropriate and when to act; how it’s diagnosed and monitored; the evidence for photodynamic therapy, thermal and subthreshold micropulse laser, tablets and eye injections; what’s emerging; recovery and relapse; self-care to reduce triggers; red flags; and how to access care in Sydney’s Eastern Suburbs.
Who is at risk and common triggers
CSC often affects young to middle‑aged adults and is more common in men. Stress and steroids are key triggers: your own cortisol or prescribed corticosteroids can allow fluid to collect under the macula. Knowing your risks helps tailor treatment for central serous chorioretinopathy and prevent relapse.
- Corticosteroids (any route) and high stress/“type A”.
- Comorbidities and life stages: high blood pressure, heart disease, pregnancy, sleep apnoea/insomnia.
- Other links: certain medicines (decongestants, stimulants, erectile‑dysfunction, some anti‑cancer), family history, male sex (30–50), myopia, H. pylori, kidney disease.
How CSC is diagnosed and monitored
Diagnosis starts with a dilated eye exam and history, including recent corticosteroid use and stress. The key test is optical coherence tomography (OCT), which shows subretinal fluid and serous detachment. Fluorescein angiography maps leakage and helps distinguish CSC from other macular diseases; indocyanine green angiography may be added in chronic cases or when planning treatment for central serous chorioretinopathy (such as photodynamic therapy).
Monitoring typically includes:
- Repeat OCT: over weeks to months to confirm fluid is resolving.
- Amsler grid: checks at home; urgent review if new distortion.
- Review triggers: steroid use and systemic factors (stress, blood pressure, sleep apnoea).
Observe or treat? How doctors decide
Because many first episodes settle on their own, doctors usually start with observation, repeat OCT scans and trigger control. The decision to shift from watching to active treatment for central serous chorioretinopathy hinges on duration, severity and risk. Treatment is considered when the disease becomes chronic, threatens lasting macular damage or complications emerge.
- Persistent or recurrent fluid: subretinal fluid after several months or frequent relapses.
- Signs of chronicity: OCT/angiography show widespread leakage or RPE damage.
- Worsening vision: significant central vision loss despite observation.
- Complications: suspected choroidal neovascularisation.
Where safe, corticosteroids are reduced or stopped in coordination with your GP. If treatment is needed, photodynamic therapy is often preferred in chronic CSC.
Photodynamic therapy (PDT): evidence, how it works, and who benefits
Photodynamic therapy (PDT) is the best‑supported active treatment for central serous chorioretinopathy when it becomes chronic. It uses an intravenous drug (verteporfin) that is activated by a low‑energy “cold” laser to shut down choroidal leakage beneath the retina without burning it. Reviews consistently find that, for persistent CSC, half‑dose or half‑fluence PDT achieves the most reliable drying of the macula; conventional thermal laser is generally reserved for when PDT is unavailable and the leak lies away from the fovea.
Clinically, PDT is considered when subretinal fluid hasn’t cleared after several months, in recurrent disease, or when the leak is under or close to the fovea where thermal laser is unsafe. Angiography and OCT guide the target and confirm response. Many eyes improve in vision as the fluid resolves, and PDT may reduce future recurrences in some eyes. Protocol choice (half‑dose/half‑fluence) is commonly used in CSC.
Laser treatment options: thermal and subthreshold micropulse
As a treatment for central serous chorioretinopathy, laser options include thermal photocoagulation and subthreshold micropulse. Thermal laser (argon photocoagulation) can seal a discrete leakage point but creates a small retinal scar, so it’s reserved for extrafoveal leaks—not under or next to the fovea. Subthreshold micropulse laser delivers very short, low‑duty pulses (smaller, shorter pulses) aiming to dry the macula while minimising collateral effects. Both are mainly considered in chronic or recurrent CSC, particularly when PDT isn’t available.
- Best candidates: focal extrafoveal leaks (thermal); cases where minimising collateral damage is a priority (micropulse).
- Considerations: outcomes vary; micropulse may need repeat sessions; PDT has the strongest evidence in chronic CSC.
Oral medications for CSC: current evidence and when to consider them
As a treatment for central serous chorioretinopathy, oral tablets have been tried, but evidence is mixed and weaker than photodynamic therapy, so they’re not first‑line. In selected chronic or recurrent cases, your specialist may consider a supervised trial—often diuretics—to help reduce macular fluid. This is usually reserved for when observation has failed or when PDT is unsuitable or unavailable. Reducing or stopping corticosteroids where medically safe is crucial; never cease high‑dose steroids abruptly—coordinate any change with your doctor. Results vary, so any tablet trial needs close OCT monitoring over several weeks.
Eye injections (anti-VEGF): when they are appropriate
Anti‑VEGF eye injections are not the default treatment for central serous chorioretinopathy because classic CSC leakage is not driven by abnormal new vessels. Their main role is when CSC is complicated by choroidal neovascularisation (CNV). In that setting, anti‑VEGF medications help stop new vessel growth and leakage, stabilising or improving vision. For uncomplicated chronic CSC, evidence for anti‑VEGF is weaker than for photodynamic therapy, so injections are generally reserved for imaging‑proven CNV; your specialist will confirm this with OCT and fluorescein/indocyanine green angiography.
What’s new and emerging in CSC treatment
Most progress in treatment for central serous chorioretinopathy centres on optimising proven therapies and better targeting. Studies support reduced‑intensity verteporfin PDT (half‑dose or half‑fluence) as the most effective option for chronic CSC, with ICG‑guided protocols to localise leakage and limit collateral effects. There’s growing interest in earlier PDT for selected acute cases to hasten fluid resolution, and in fine‑tuning subthreshold micropulse settings. Pharmacological strategies and selective use of anti‑VEGF are being evaluated, but PDT remains the reference treatment when observation fails.
Recovery timeline, recurrence, and long-term outlook
Most first episodes of CSC resolve on their own as the fluid reabsorbs, typically within one to four months. As the macula dries, vision usually improves, often returning to normal, though mild distortion or colour desaturation can linger in some people. If fluid persists for several months or keeps recurring, active treatment (especially reduced‑dose photodynamic therapy) is used to protect the macula.
Recurrence is common: up to half of patients may have another episode within a year, and it can affect either eye. With evidence‑based treatment for central serous chorioretinopathy and trigger control, the long‑term outlook is favourable. PDT may also reduce future recurrences in some eyes. Rarely, a complication called choroidal neovascularisation develops and is treated with anti‑VEGF injections. Regular OCT reviews help catch relapse early.
Self-care to reduce relapse risk (stress, steroids, sleep, blood pressure)
Self-care can lower relapse risk and support the effect of treatment for central serous chorioretinopathy. Because stress hormones and corticosteroids are key drivers, a few targeted habits plus coordination with your GP make a real difference. These steps don’t replace PDT or laser when needed, but they help stabilise the macula.
- Coordinate steroid use: never stop abruptly; taper only with your GP.
- Manage stress consistently: exercise, mindfulness, counselling, and realistic workloads.
- Sleep matters: aim 7+ hours; limit late caffeine; assess for sleep apnoea.
- Control blood pressure and cardiovascular risk: monitor, treat and follow advice.
- Check other medicines: decongestants, stimulants and ED drugs may worsen CSC.
Red flags: when to seek urgent care
Most CSC can be watched, but some symptoms need same‑day assessment. Even if you’re being observed or have had treatment for central serous chorioretinopathy, seek care immediately—don’t wait for your next routine review—if you notice any of the following. Prompt action can protect the macula and prevent permanent vision changes.
- Sudden vision drop: new dark spot or rapidly worsening distortion.
- On corticosteroids with new vision symptoms: call your specialist; don’t stop abruptly.
- Eye pain + visual change: not typical for CSC; urgent review.
- Amsler grid change: new or rapidly enlarging distortion.
Accessing CSC care in Sydney’s Eastern Suburbs
Patients in Randwick, Maroubra, Kensington, Bondi and Waverley can access Bright Sight Eye Specialists for assessment and treatment for central serous chorioretinopathy. Led by Dr Rahul Dubey (Moorfields‑trained), we provide OCT‑guided diagnosis and monitoring, with fluorescein/ICG angiography arranged when needed, trigger review, and options including observation, laser where suitable, and intravitreal injections if CNV develops. Expect transparent pricing with many procedures no‑gap or known gap for insured patients, plus coordinated care with your GP.
Bringing it all together
CSC often settles on its own, so early care centres on diagnosis, OCT monitoring and removing triggers. When fluid persists or recurs, reduced‑dose photodynamic therapy has the best evidence for drying the macula. Thermal or subthreshold micropulse laser suit selected extrafoveal leaks. Anti‑VEGF injections are reserved for confirmed CNV. Tablets have limited evidence. With timely treatment, self‑care and follow‑up, most people stabilise despite recurrences.
In Sydney’s Eastern Suburbs, book an assessment with Bright Sight Eye Specialists for clear diagnosis, evidence‑based options and transparent costs, including many no‑gap or known‑gap procedures for insured patients. We’ll coordinate care with your GP and keep you informed at every step.